clinical trial · NCT07291323
Study of JANX011 in Healthy Adult Volunteers to Assess Safety and Tolerability.
AutoimmuneJANX011
brief summary
This first-in-human (FIH) study aims to characterize the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of JANX011 dosed subcutaneously (and potentially intravenously) in healthy adult volunteers (HVs) to gain insight into its therapeutic utility in patients with autoimmune diseases.
started
Feb 16, 2026
primary completion
Oct 1, 2026
completion
Dec 1, 2026
last updated
Apr 23, 2026
official title
A Phase 1, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of JANX011 With Optional Step-Up Dosing in Healthy Adult Volunteers
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol